San Francisco, CA / Berlin, Germany -- April 7, 2021 -- T-knife
Therapeutics, Inc., a next-generation T-cell receptor company developing
innovative therapeutics for the benefit of solid tumor patients and
their families, today announced the appointment of Donald Wuchterl as
Senior Vice President and Chief Manufacturing Officer. In this newly
appointed role, Mr. Wuchterl will oversee process and analytical
development, quality assurance and quality control, and viral vector and
cell therapy manufacturing activities.
"I am very pleased to welcome Don to the T-knife team," stated Thomas M.
Soloway, Chief Executive Officer of T-knife. "Don's proven track-record
of building and leading highly functioning cell therapy, biologics and
gene therapy manufacturing organizations will be a significant asset to
our platform and development programs. We look forward to the
contributions Don will make as we advance our lead program targeting
MAGE-A1 into the clinic later this year and continue to build a leading
pipeline of innovative TCR-T product candidates."
"I am honored to join the T-knife executive team at this important
inflection point in the company's development," said Mr. Wuchterl.
"T-knife has established itself as an emerging leader in the field of
TCR-T cell therapy and is well positioned for meaningful near-term
catalysts. I look forward to working with the T-knife team to deliver on
the promise of its HuTCR platform to provide transformative benefits for
solid tumor cancer patients."
Mr. Wuchterl brings over 29 years of experience in the life sciences
industries, with senior roles in operations and CMC. He has significant
experience building and leading cGMP organizations and facilities. He
joins T-knife from Audentes Therapeutics (an Astellas Company), a gene
therapy company focused on developing and commercializing innovative
products for patients living with serious, life-threatening rare
neuromuscular diseases, where he most recently served as Senior Vice
President, Technical Operations & Quality. Prior to Audentes, Mr.
Wuchterl served as Senior Vice President and Chief Operating Officer at
Cytovance Biologics, a leading biopharmaceutical contract manufacturing
company. Prior to Cytovance, Mr. Wuchterl held positions of increasing
responsibility with Dendreon, Shire HGT, Amgen, Biogen Idec and Roche.
Mr. Wuchterl has a B.S. in Business Administration from Colorado
Technical University and an M.B.A. from Fitchburg State University.
About T-knife Therapeutics
T-knife is a next-generation T-cell receptor company developing a
pipeline of innovative therapeutics for the benefit of solid tumor
patients and their families. The company leverages its proprietary
humanized T-cell receptor (HuTCR) transgenic mouse platform to produce
fully-human TCRs, naturally selected in-vivo for high affinity and
specificity. T-knife is developing a pipeline of first / best-in-class
TCR therapeutics against targets with high unmet medical need, including
cancer testis antigens, viral antigens and commonly shared neo antigens.
T-knife was founded by leading T-cell and immunology experts using
technology developed at the Max Delbruck Center for Molecular Medicine
together with Charité University Hospital in Berlin, and is backed
by leading investors, including RA Capital, Versant Ventures, Andera
Partners and Boehringer Ingelheim Venture Fund.
Contact T-knife Therapeutics, Inc.
Camille Landis, CBO/CFO
Tel.: +49 30 94892432
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
(END) Dow Jones Newswires
April 07, 2021 06:00 ET (10:00 GMT)